Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iniparib SCHEMBL29354973 | 1.00 | PARP1 (1.00) | PARP1GAAALDH1A1PKML3MBTL1 | |
| SCHEMBL10954211 | 0.85 | PARP1 (0.74) | PARP1ALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL1766442 | 0.84 | PARP1 (0.72) | PARP1TSHRLMNACASP6 | |
| SCHEMBL30995722 | 0.84 | PARP1 (0.72) | PARP1TSHRLMNACASP6 | |
| SCHEMBL8629267 | 0.84 | PARP1 (0.72) | PARP1GAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL15427439 | 0.84 | PARP1 (0.72) | PARP1GAAALDH1A1PKML3MBTL1 | |
| SCHEMBL1254186 | 0.83 | PARP1 (0.71) | PARP1GAAALDH1A1PKML3MBTL1 | |
| SCHEMBL27901177 | 0.82 | PARP1 (0.69) | PARP1ALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL3181806 | 0.82 | PARP1 (0.70) | PARP1ALDH1A1PKML3MBTL1TSHR | |
| SCHEMBL1767399 | 0.82 | PARP1 (0.70) | PARP1ALDH1A1TSHRLMNACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713017-A1 | CHIMERIC MOLECULE | UCL Business Ltd (GB) | 2026-03-25 | — | — | EP | claimed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2024236326-A1 | CHIMERIC MOLECULE | UCL BUSINESS LTD (GB) | 2024-11-21 | — | — | WO | claimed |
| US-20240335465-A1 | A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-10 | — | — | US | claimed |
| CN-117106735-B | Recombinant viral vector and pseudovirus of Nib virus, and preparation method and application thereof | 中山大学 | 2024-06-18 | — | — | CN | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | claimed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | claimed |
| CN-117106735-A | Recombinant viral vector and pseudovirus of Nib virus, and preparation method and application thereof | 中山大学 | 2023-11-24 | — | — | CN | claimed |
| CN-114939418-B | Pd-containing device 1 Monoatomic catalyst with M/carrier structure and application thereof | 北京单原子催化科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | claimed |
| US-20080319054-A1 | Treatment of Cancer | BIPAR SCIENCES, INC. | 2008-12-25 | — | — | US | claimed |
| CN-101190211-A | Application of aromatic nitro compound in preparing medicine for treating virus hepatitis | CRIMSON PHARMACEUTICAL SHANGHA (CN) | 2008-06-04 | — | — | CN | claimed |
| CN-1768733-A | Application of aromatic nitro compound in preparation of medicine for treating AIDS | CRIMSON PHARMACEUTICAL (CN) | 2006-05-10 | — | — | CN | claimed |
| CN-1768732-A | Application of aromatic nitro compound in preparation of medicine for treating tumor | CRIMSON PHARMACEUTICAL (CN) | 2006-05-10 | — | — | CN | claimed |
| US-5877185-A | THERAPY FOR CANCER OR RETROVIRUS | OCTAMER, INC. (US) | 1999-03-02 | — | — | US | claimed |
| EP-0698019-B1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER INC (US) | 1998-08-05 | — | — | EP | claimed |
| WO-1996022791-A9 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | — | 1996-10-03 | — | — | WO | claimed |
| WO-1996022791-A1 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | OCTAMER, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| EP-0698019-A1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1996-02-28 | — | — | EP | claimed |
| WO-1994026730-A2 | NOVEL AROMATIC NITRO AND NITROSO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1994-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319054-A1 | Treatment of Cancer | PARP1, PARP2, PARP3 | PARP1 1/4885GAA 253/4885ALDH1A1 794/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885GAA 992/4885ALDH1A1 3441/4885 |
| US-20240335465-A1 | A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING | CGAS, ATM, CHEK2 | PARP1 37/4885GAA 1735/4885ALDH1A1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.